Editorial: Iron overload in myelodysplastic syndromes

Expert Review of Hematology

Volumn 2, Issue 3, 2009, Pages 215-218

  Chodirker, Lisa ^a   Wells, Richard A ^b  

^a DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT;

ABDOMINAL PAIN; ACUTE LEUKEMIA; DIARRHEA; EDITORIAL; ERYTHROCYTE TRANSFUSION; FERRITIN BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HUMAN; IRON ABSORPTION; IRON CHELATION; IRON OVERLOAD; MYELODYSPLASTIC SYNDROME; NAUSEA; PRIORITY JOURNAL; RASH; BLOOD; METABOLISM;

HUMANS; IRON CHELATING AGENTS; IRON OVERLOAD; MYELODYSPLASTIC SYNDROMES;

EID: 77953373930     PISSN: 17474086     EISSN: None     Source Type: Journal    
DOI: 10.1586/ehm.09.23     Document Type: Editorial

References (48)

1. Cazzola M, Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N. Engl. J. Med. 352(6), 536-538 (2005).
2. A randomized double-blind placebocontrolled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. Br. J. Haematol. 103(4), 1070-1074 (1998).
3. Porter JB. Practical management of iron overload. Br. J. Haematol. 115(2), 239-252 (2001).
4. Mahesh S, Ginzburg Y, Verma A. Iron overload in myelodysplastic syndromes. Leuk. Lymphoma 49(3), 427-438 (2008).
5. Mittelman M, Lugassy G, Merkel D et al. Iron chelation therapy in patients with myelodysplastic syndromes: consensus conference guidelines. Isr. Med. Assoc. J. 10(5), 374-376 (2008).
6. Valent P, Krieger O, Stauder R et al. Iron overload in myelodysplastic syndromes (MDS) - diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur. J. Clin. Invest. 38(3), 143-149 (2008).
7. Greenberg PL. Myelodysplastic syndromes: iron overload consequences and current chelating therapies. J. Natl Compr. Canc. Netw. 4(1), 91-96 (2006).
8. Rose C, Cambier N, Mahieu M, Ernst O, Fenaux P. [Iron overload and myelodysplastic syndromes]. Transfus. Clin. Biol. 8(5), 422-432 (2001).
9. Bennett JM. Consensus statement on iron overload in myelodysplastic syndromes. Am. J. Hematol. 83(11), 858-861 (2008).
10. Alessandrino EP, Amadori S, Barosi G et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 87(12), 1286-1306 (2002).
11. Jabbour E, Kantarjian HM, Koller C, Taher A. Red blood cell transfusions and iron overload in the treatment of patients with myelodysplastic syndromes. Cancer 112(5), 1089-1095 (2008).
12. Gattermann N. Overview of guidelines on iron chelation therapy in patients with myelodysplastic syndromes and transfusional iron overload. Int. J. Hematol. 88(1), 24-29 (2008).
13. Bowen D, Culligan D, Jowitt S et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. Haematol. 120(2), 187-200 (2003).
14. Wells RA, Leber B, Buckstein R et al. Iron overload in myelodysplastic syndromes: a Canadian consensus guideline. Leuk. Res. 32(9), 1338-1353 (2008).
15. Weintraub LR, Conrad ME, Crosby WH. Regulation of the intestinal absorption of iron by the rate of erythropoiesis. Br. J. Haematol. 11, 432-438 (1965).
16. Nemeth E, Tuttle MS, Powelson J et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 306(5704), 2090-2093 (2004).
17. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu. Rev. Nutr. 26, 323-342 (2006).
18. Papanikolaou G, Tzilianos M, Christakis JI et al. Hepcidin in iron overload disorders. Blood 105(10), 4103-4105 (2005).
19. Winder A, Lefkowitz R, Ghoti H et al. Urinary hepcidin excretion in patients with myelodysplastic syndrome and myelofibrosis. Br. J. Haematol. 142(4), 669-671 (2008).
20. Ramirez JM, Schaad O, Durual S et al. Growth differentiation factor 15 production is necessary for normal erythroid differentiation and is increased in refractory anaemia with ring-sideroblasts. Br. J. Haematol. 144(2), 251-262 (2009).
21. Tanno T, Bhanu NV, Oneal PA et al. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin. Nat. Med. 13(9), 1096-1101 (2007).
22. Tamary H, Shalev H, Perez-Avraham G et al. Elevated growth differentiation factor 15 expression in patients with congenital dyserythropoietic anemia type I. Blood 112(13), 5241-5244 (2008).
23. Finkenstedt A, Bianchi P, Theurl I et al. Regulation of iron metabolism through GDF15 and hepcidin in pyruvate kinase deficiency. Br. J. Haematol. 144(5), 789-793 (2009).
24. Breuer W, Hershko C, Cabantchik ZI. The importance of non-transferrin bound iron in disorders of iron metabolism. Transfus. Sci. 23(3), 185-192 (2000).
25. Breuer W, Ronson A, Slotki IN et al. The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation. Blood 95(9), 2975-2982 (2000).
26. Esposito BP, Breuer W, Sirankapracha P et al. Labile plasma iron in iron overload: redox activity and susceptibility to chelation. Blood 102(7), 2670-2677 (2003).
27. Cortelezzi A, Cattaneo C, Cristiani S et al. Non-transferrin-bound iron in myelodysplastic syndromes: a marker of ineffective erythropoiesis? Hematol. J. 1(3), 153-158 (2000).
28. Breuer W, Ermers MJ, Pootrakul P et al. Desferrioxamine-chelatable iron, a component of serum non-transferrinbound iron, used for assessing chelation therapy. Blood 97(3), 792-798 (2001).
29. Wang WC, Ahmed N, Hanna M. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias. J. Pediatr. 108(4), 552-557 (1986).
30. Pootrakul P, Breuer W, Sametband M et al. Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded b-thalassemia/HbE patients treated with an oral chelator. Blood 104(5), 1504-1510 (2004).
31. Jaeger M, Aul C, Sohngen D, Germing U, Schneider W. [Secondary hemochromatosis in polytransfused patients with myelodysplastic syndromes]. Beitr. Infusionsther. 30, 464-468 (1992).
32. Cazzola M, Barosi G, Gobbi PG et al. Natural history of idiopathic refractory sideroblastic anemia. Blood 71(2), 305-312 (1988).
33. Delea TE, Hagiwara M, Phatak PD. Retrospective study of the association between transfusion frequency and potential complications of iron overload in patients with myelodysplastic syndrome and other acquired hematopoietic disorders. Curr. Med. Res. Opin. 25(1), 139-147 (2009).
34. Goldberg SL, Mody-Patel N, Chen ER. Clinical and economic consequences of myelodysplastic syndromes in the United States: an analysis of the medicare database. Blood 112(11), A237 (2008) (Abstract 636).
35. Malcovati L, Porta MG, Pascutto C et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 23(30), 7594-7603 (2005).
36. Garcia-Manero G, Shan J, Faderl S et al. A prognostic score for patients with lower risk myelodysplastic syndrome. Leukemia 22(3), 538-543 (2008).
37. Takatoku M, Uchiyama T, Okamoto S et al. Retrospective nationwide survey of Japanese patients with transfusiondependent MDS and aplastic anemia highlights the negative impact of iron overload on morbidity/mortality. Eur. J. Haematol. 78(6), 487-494 (2007).
38. Sanz G, Nomdedeu B, Such E et al. Independent impact of iron overload and transfusion dependency on survival and leukemic evolution in patients with myelodysplastic syndrome. Blood 112(11), 238a-239a (2008) (Abstarct 640).
39. Chan LSA, Buckstein R, Reis MD et al. Iron overload and haematopoiesis in MDS: does blood transfusion promote progression to AML? Blood 112(11), A928 (2008) (Abstract 2685).
40. Kersten MJ, Lange R, Smeets ME et al. Long-term treatment of transfusional iron overload with the oral iron chelator deferiprone (L1): a Dutch multicenter trial. Ann. Hematol. 73(5), 247-252 (1996).
41. Gattermann N, Schmid M, Della Porta M et al. Efficacy and safety of deferasirox (Exjade) during 1 year of treatment in transfusion-dependent patients with myelodsysplastic syndromes: results from EPIC Trial. Blood 112(11), A235-A236 (2008) (Abstract 633).
42. Jensen PD, Jensen FT, Christensen T et al. Evaluation of myocardial iron by magnetic resonance imaging during iron chelation therapy with deferrioxamine: indication of close relation between myocardial iron content and chelatable iron pool. Blood 101(11), 4632-4639 (2003).
43. Porter J, Galanello R, Saglio G et al. Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study. Eur. J. Haematol. 80(2), 168-176 (2008).
44. Cappellini MD, Cohen A, Piga A et al. A Phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with b-thalassemia. Blood 107(9), 3455-3462 (2006).
45. List AF, Baer MR, Steensma DP, Raza A. Iron chelation with deferasirox (Exjade) improves iron burden in patients with myelodysplastic syndrome (MDS). Blood 112(11), A236 (2008) (Abstract 634) .
46. Rachmilewitz E, Merkel D, Ghoti H et al. Improvement of oxidative stress parameters in MDS patients with iron overload treated with deferasirox. Blood 112(11), A924-A925 (2008) (Abstract 2675).
47. Leitch HA, Leger CS, Goodman TA et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin. Leuk. 2, 205-211 (2008).
48. Rose C, Brechignac S, Vassilief D et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Blood 110(11), A80-A81 (2007) (Abstract 249).